Kancera AB (KAN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kancera AB (KAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8202
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kancera AB (Kancera) is a developer of drug candidates for the treatment of cancer. The company’s pipeline products include fractalkine inhibitor AZD8797, used to stop tumor growth; small molecule HDAC6 inhibitors, for neutralizing blood cancer; small molecule PFKFB3 inhibitors, for stopping energy supply from glucose to solid tumors; small molecule ROR inhibitors, for to reprogram cancer cells to destroy themselves, and small molecule inhibitors of epigenetic processes in parasites for developing new treatments to malaria and schistosomiasis. It caters to pharmaceutical and biotechnology companies. The company operates through its facility located in Stockholm, Sweden. Kancera is headquartered in Stockholm, Sweden.

Kancera AB (KAN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kancera AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kancera AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kancera AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kancera AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kancera AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kancera AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Kancera Acquires Fractalkine Project from Acturum 10
Partnerships 11
Kancera and Recipharm Enter into Partnership 11
Kancera Enters into Co-Development Agreement with Acturum Life Science 12
Equity Offering 13
Kancera to Raise USD6.4 Million in Rights Offering of Units 13
Kancera Raises USD1.4 Million in Rights offering of Shares 14
Kancera AB – Key Competitors 15
Kancera AB – Key Employees 16
Kancera AB – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Jun 07, 2018: Interim-report for Kancera 1st January – 31st March 2018 18
Aug 23, 2017: Interim Report for Kancera for January 1st – June 30th 2017 20
Aug 22, 2017: Kancera Announces Its Interim Report Q2 2017 21
Feb 21, 2017: Interim Report for Kancera Q4 2016. January 1St – December 31St 2016 23
Other Significant Developments 25
Feb 21, 2017: Kancera Provides Operational Update Of The Project Portfolio 25
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Kancera AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kancera AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kancera AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kancera AB, Deals By Therapy Area, 2012 to YTD 2018 8
Kancera AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kancera Acquires Fractalkine Project from Acturum 10
Kancera and Recipharm Enter into Partnership 11
Kancera Enters into Co-Development Agreement with Acturum Life Science 12
Kancera to Raise USD6.4 Million in Rights Offering of Units 13
Kancera Raises USD1.4 Million in Rights offering of Shares 14
Kancera AB, Key Competitors 15
Kancera AB, Key Employees 16
Kancera AB, Subsidiaries 17

List of Figures
Kancera AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kancera AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kancera AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kancera AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kancera AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kancera AB (KAN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PepsiCo Inc:戦略・SWOT・企業財務分析
    PepsiCo Inc - Strategy, SWOT and Corporate Finance Report Summary PepsiCo Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Aabar Investments:企業の戦略的SWOT分析
    Aabar Investments - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • SPAGO Nanomedical AB-医療機器分野:企業M&A・提携分析
    Summary Spago Nanomedical AB (SPAGO Nanomedical), formerly SPAGO Imaging AB is a drug company that develops proprietary magnetic resonance imaging contrast agent, and the novel therapeutic project tumorad for cancer selective radionuclide treatment. The company concentrates on research and developme …
  • Corizon Health Inc:企業の戦略的SWOT分析
    Corizon Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Mitsui & Co., Ltd.:企業の戦略・SWOT・財務分析
    Mitsui & Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsui & Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Consejo Superior de Investigaciones Cientificas-製薬・医療分野:企業M&A・提携分析
    Summary Consejo Superior de Investigaciones Cientificas (CSIC) is a research institute that provides research capacity, and human and material resources to conduct research projects. The institute offers multidisciplinary scientific and technical research, scientific and technical advice, management …
  • Akcansa Cimento Sanayi ve Ticaret AS:企業の戦略・SWOT・財務情報
    Akcansa Cimento Sanayi ve Ticaret AS - Strategy, SWOT and Corporate Finance Report Summary Akcansa Cimento Sanayi ve Ticaret AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Emcure Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Emcure Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Debt Resolve Inc (DRSV):企業の財務・戦略的SWOT分析
    Summary Debt Resolve Inc (Debt Resolve) is a technology company that offers cloud-based software and services. The company develops and markets patent-based web collection technologies. It provides solutions for non-payment of bills, debts, damages and other financial disputes. Debt Resolve also off …
  • Sensus Healthcare Inc (SRTS):企業の製品パイプライン分析2018
    Summary Sensus Healthcare Inc (Sensus) designs, manufactures and markets proprietary medical devices for the treatment of various types of cancers and skin diseases. The company offers superficial radiation therapy (SRT) technology based non-surgical treatment options for patients suffering from var …
  • GW Pharmaceuticals Plc (GWPH):製薬・医療:M&Aディール及び事業提携情報
    Summary GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the …
  • Iowa Health System:企業の戦略的SWOT分析
    Iowa Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Cybernet Systems Corporation:企業の戦略・SWOT・財務情報
    Cybernet Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary Cybernet Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • SLEEP NUMBER CORP:企業の戦略・SWOT・財務情報
    SLEEP NUMBER CORP - Strategy, SWOT and Corporate Finance Report Summary SLEEP NUMBER CORP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Unified Grocers, Inc.:企業の戦略的SWOT分析
    Unified Grocers, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Syros Pharmaceuticals Inc (SYRS):企業の財務・戦略的SWOT分析
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • PPL Corporation:企業の戦略・SWOT・財務情報
    PPL Corporation - Strategy, SWOT and Corporate Finance Report Summary PPL Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Crescita Therapeutics Inc (CTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Crescita Therapeutics Inc (Crescita Therapeutics) is a commercial dermatology company that offers prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. The company’s products comprise Pliaglis, Alyria, Laboratoire Dr Renaud, Pro-Derm, Premi …
  • Pakistan International Airlines Corporation
    Pakistan International Airlines Corporation - Strategy, SWOT and Corporate Finance Report Summary Pakistan International Airlines Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Nippon Yusen Kabushiki Kaisha (9101)-石油・ガス分野:企業M&A・提携分析
    Summary Nippon Yusen Kabushiki Kaisha (NYK) is a logistics company transporting crude oil and allied products. The company provides ocean, land, and air transport services for the transportation of petroleum products, liquid products and dry bulk products. Its portfolio includes line trade, air carg …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆